Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) CFO Marc Wilson sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $28.75, for a total transaction of $287,500.00. Following the completion of the transaction, the chief financial officer now owns 95,601 shares in the company, valued at approximately $2,748,528.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Crinetics Pharmaceuticals Price Performance
Crinetics Pharmaceuticals stock opened at $30.70 on Monday. The company has a market cap of $1.68 billion, a PE ratio of -9.00 and a beta of 0.56. The company has a fifty day moving average price of $26.15 and a two-hundred day moving average price of $21.99. Crinetics Pharmaceuticals, Inc. has a 12 month low of $15.23 and a 12 month high of $31.41.
Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.09). The business had revenue of $0.99 million during the quarter, compared to analyst estimates of $5.00 million. Crinetics Pharmaceuticals had a negative return on equity of 61.19% and a negative net margin of 3,804.10%. Equities research analysts anticipate that Crinetics Pharmaceuticals, Inc. will post -3.52 earnings per share for the current year.
Hedge Funds Weigh In On Crinetics Pharmaceuticals
Analysts Set New Price Targets
A number of analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $33.00 price objective on shares of Crinetics Pharmaceuticals in a research note on Monday, September 11th. JMP Securities dropped their price target on shares of Crinetics Pharmaceuticals from $43.00 to $42.00 and set a “market outperform” rating for the company in a research note on Wednesday, August 9th. Evercore ISI lifted their price target on shares of Crinetics Pharmaceuticals from $41.00 to $48.00 and gave the stock an “outperform” rating in a research note on Monday, September 11th. Oppenheimer lifted their price target on shares of Crinetics Pharmaceuticals from $40.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, September 11th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $50.00 price target (down previously from $52.00) on shares of Crinetics Pharmaceuticals in a research note on Tuesday, October 24th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $45.71.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).
- Five stocks we like better than Crinetics Pharmaceuticals
- What is the Dogs of the Dow Strategy? Overview and Examples
- MarketBeat Week in Review – 10/30 – 11/3
- Comparing and Trading High PE Ratio Stocks
- Shocking uranium play that hedge funds kept hidden
- What Investors Need to Know to Beat the Market
- Dependable dividends: Why utility stocks are on fire
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.